A Phase 4 interventional study of Oxycodone/Naloxone and Oxycodone(single compound) in Cancer, sponsored by Mundipharma Korea Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-12-22.
Sponsored by Mundipharma Korea Ltd (part of Mundipharma) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Objectives:
To prove non-inferiority of Targin compared to Oxycontin in terms of change of pain intensity
This will be a 4-week multicentre, randomized, open label, parallel group, active control study to evaluate efficacy and safety of Targin in comparison with Oxycontin in Korean patients with cancer pain who are administered weak opioid or naïve patients including patient not on the long term strong opioid medication within 3 months.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 128 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Mundipharma Korea Ltd is the lead sponsor of 16 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women of , defined as all women physiologically capable of becoming pregnant. UNLESS they are:
If subjects started first cycle of chemotherapy during the 2 weeks before the screening visit or during the study, they should be excluded from the study.
And If the chemotherapy regimen or dosage to be planned to change during the study, the subjects should be excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trade name is Targin(fixed combination drug).
Drug: Oxycodone/Naloxone
Trade name is Oxycontin(single compound).
Drug: Oxycodone(single compound)
Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3)
Change of pain intensity from 0(No pain) to 10(worst pain imaginable) after 4 weeks treatment .
Time frame: 4weeks
Change in Bowel Habits.
The change of bowel habits from baseline (Visit 1) in bowel habits at Week 4 was investigated, and was categorized as 'improved', 'unchanged', and 'worsened'.
Time frame: 4 weeks
ITT set(Safety analysis) was 128(64:64) patients, but Missing primary efficacy data: 7 patients, Violation of inclusion/exclusion criteria: 4. So, FAS(Efficacy analysis) set population was 117(oxycodone/naloxone group: 58: Oxycodone: 59).
| Milestone | Oxycodone and Naloxone | Oxycodone |
|---|---|---|
| Started | 58 | 59 |
| Completed | 33 | 31 |
| Not completed | 25 | 28 |
| Withdrew: Lack of efficacy | 4 | 2 |
| Withdrew: Adverse event | 6 | 11 |
| Withdrew: Withdrawal by subject | 2 | 8 |
| Withdrew: Protocol violation | 10 | 4 |
| Withdrew: Missing data | 3 | 3 |
Change of pain intensity from 0(No pain) to 10(worst pain imaginable) after 4 weeks treatment .
| units on a scale | Oxycodone and Naloxone | Oxycodone |
|---|---|---|
| Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3) | 1.586 ± 2.217 | 1.559 ± 2.215 |
The change of bowel habits from baseline (Visit 1) in bowel habits at Week 4 was investigated, and was categorized as 'improved', 'unchanged', and 'worsened'.
| participants | Oxycodone and Naloxone | Oxycodone |
|---|---|---|
| Unchanged | 31 | 20 |
| worsened | 7 | 11 |
| Improved | 5 | 5 |
Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxycodone and Naloxone | — | 15/64 (23.4%) | 55/64 (85.9%) |
| Oxycodone | — | 28/64 (43.8%) | 57/64 (89.1%) |
| Event | Oxycodone and Naloxone | Oxycodone |
|---|---|---|
| pneumoniaInfections and infestations | 2/64 | 0/64 |
| Glucose, serum-low (hypoglycemia)Metabolism and nutrition disorders | 2/64 | 0/64 |
| PainGeneral disorders | 1/64 | 2/64 |
| anaphylactic shockImmune system disorders | 0/64 | 1/64 |
| leukocytosisInvestigations | 0/64 | 1/64 |
| neutropeniaInvestigations | 1/64 | 0/64 |
| ThrombocytopeniaInvestigations | 0/64 | 1/64 |
| FeverGeneral disorders | 1/64 | 0/64 |
| General condition worseGeneral disorders | 0/64 | 1/64 |
| SweatingGeneral disorders | 0/64 | 1/64 |
| Event | Oxycodone and Naloxone | Oxycodone |
|---|---|---|
| ConstipationGastrointestinal disorders | 30/64 | 35/64 |
| NauseaGastrointestinal disorders | 10/64 | 18/64 |
| DizzinessNervous system disorders | 6/64 | 14/64 |
| AnorexiaGastrointestinal disorders | 8/64 | 4/64 |
| VomitingGastrointestinal disorders | 8/64 | 7/64 |
| DiarrheaGastrointestinal disorders | 4/64 | 1/64 |
| Dyspnea (shortness of breath)Respiratory, thoracic and mediastinal disorders | 0/64 | 4/64 |
| Fatigue (asthenia, lethargy, malaise)General disorders | 3/64 | 3/64 |
| InsomniaNervous system disorders | 3/64 | 1/64 |
| Pruritus/itchingSkin and subcutaneous tissue disorders | 2/64 | 3/64 |
| Age, Customized(participants) | Oxycodone and Naloxone | Oxycodone | Total |
|---|---|---|---|
| <39years | 1 | 3 | 4 |
| 40~49years | 7 | 5 | 12 |
| 50~59years | 19 | 17 | 36 |
| 60~69 years | 14 | 23 | 37 |
| 70~79 years | 17 | 11 | 28 |
| Sex: Female, Male(Participants) | Oxycodone and Naloxone | Oxycodone | Total |
|---|---|---|---|
| Female | 15 | 20 | 35 |
| Male | 43 | 39 | 82 |
| Region of Enrollment(participants) | Oxycodone and Naloxone | Oxycodone | Total |
|---|---|---|---|
| Korea, Republic of | 58 | 59 | 117 |
Plan to share: No
The record gives a start of May 2011, a primary completion of Oct 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxycodone · Naloxone